← Back to Screener
US Stock Screener
HomeScreensNewsWatchlist
...

Hims & Hers Health, Inc. (HIMS) 10-Year Financial Performance & Capital Metrics

HIMS • • Industrial / General
HealthcareMedical EquipmentTelehealth & Digital Health PlatformsMulti-Specialty Telehealth Platforms
AboutHims & Hers Health, Inc. operates a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals. The company offers a range of health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supplement products, primarily focusing on wellness, sexual health and wellness, skincare, and hair care. The company's curated non-prescription products include vitamin C, melatonin, biotin, and collagen protein supplements in the wellness category; moisturizer, serums, and face wash in the skincare category; condoms, climax delay spray and wipes, vibrators, and lubricants in the sexual health and wellness category; and shampoos, conditioners, scalp scrubs, and topical treatments, such as minoxidil in the hair care category. In addition, it offers medical consultation services, as well as health and wellness products through wholesale partners. The company is based in San Francisco, California.Show more
  • Revenue $1.48B +69.3%
  • EBITDA $79M +496.2%
  • Net Income $126M +635.3%
  • EPS (Diluted) 0.53 +581.8%
  • Gross Margin 79.45% -3.1%
  • EBITDA Margin 5.35% +334.0%
  • Operating Margin 4.19% +224.1%
  • Net Margin 8.54% +416.1%
  • ROE 30.71% +527.7%
  • ROIC 17.69% +311.3%
  • Debt/Equity 0.02 -17.7%
  • Interest Coverage -
Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

  • ✓Company is almost debt free
  • ✓High quality earnings: Operating CF exceeds net income
  • ✓Strong 5Y sales CAGR of 78.0%
  • ✓Efficient asset utilization: 2.1x turnover

✗Weaknesses

  • ✗Weak 3Y average ROE of 1.1%
  • ✗Weak momentum: RS Rating 11 (bottom 11%)
  • ✗Shares diluted 13.1% in last year
  • ✗Trading more than 30% below 52-week high
  • ✗Expensive at 15.5x book value

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-
5Y78.03%
3Y75.77%
TTM78.02%

Profit (Net Income) CAGR

10Y-
5Y-
3Y-
TTM32.13%

EPS CAGR

10Y-
5Y-
3Y-
TTM24.86%

ROCE

10Y Avg-38.46%
5Y Avg-17.22%
3Y Avg-4.95%
Latest14.76%

Peer Comparison

Multi-Specialty Telehealth Platforms
Select Columns
Size & Scale
Valuation
Per Share
Growth
Profitability
Quality & Returns
Safety & Leverage
TTM Growth
Famous Investor Metrics
Dividends
Latest Quarter
Momentum & Returns
Total Return (DRIP)
Technical
Volume & Trading
Shares & Dilution
Sector-Specific
NameMarket CapCurrent PriceP/E RatioRevenue Growth 1YNet MarginROEFCF YieldDebt/Equity
HIMSHims & Hers Health, Inc.6.85B31.2358.9269.33%6.05%23.03%2.9%0.02

Profit & Loss

Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Sales/Revenue+82.56M148.76M271.88M526.92M872M1.48B
Revenue Growth %-0.8%0.83%0.94%0.65%0.69%
Cost of Goods Sold+37.95M39.31M67.38M118.19M157.05M303.38M
COGS % of Revenue0.46%0.26%0.25%0.22%0.18%0.21%
Gross Profit+44.6M109.45M204.49M408.72M714.95M1.17B
Gross Margin %0.54%0.74%0.75%0.78%0.82%0.79%
Gross Profit Growth %-1.45%0.87%1%0.75%0.64%
Operating Expenses+119.02M124.59M319.54M477.42M744.4M1.11B
OpEx % of Revenue1.44%0.84%1.18%0.91%0.85%0.75%
Selling, General & Admin119.02M113.36M249.56M370.78M576.32M846.61M
SG&A % of Revenue1.44%0.76%0.92%0.7%0.66%0.57%
Research & Development011.24M22.38M29.24M48.23M78.82M
R&D % of Revenue-0.08%0.08%0.06%0.06%0.05%
Other Operating Expenses0047.59M77.4M119.86M185.8M
Operating Income+-74.41M-15.14M-115.04M-68.7M-29.45M61.9M
Operating Margin %-0.9%-0.1%-0.42%-0.13%-0.03%0.04%
Operating Income Growth %-0.8%-6.6%0.4%0.57%3.1%
EBITDA+-74.15M-14.09M-110.97M-61.22M-19.94M78.99M
EBITDA Margin %-0.9%-0.09%-0.41%-0.12%-0.02%0.05%
EBITDA Growth %-0.81%-6.88%0.45%0.67%4.96%
D&A (Non-Cash Add-back)260K1.06M4.08M7.47M9.52M17.09M
EBIT-71.61M-15.14M-115.04M-68.7M-29.45M61.9M
Net Interest Income+-369K-10K0000
Interest Income000000
Interest Expense369K10K0000
Other Income/Expense2.44M-2.84M4.25M2.99M7.88M9.81M
Pretax Income+-71.97M-17.99M-110.8M-65.71M-21.57M71.71M
Pretax Margin %-0.87%-0.12%-0.41%-0.12%-0.02%0.05%
Income Tax+90K127K-3.14M-31K1.98M-54.33M
Effective Tax Rate %1%1.01%0.97%1%1.09%1.76%
Net Income+-72.06M-18.11M-107.66M-65.68M-23.55M126.04M
Net Margin %-0.87%-0.12%-0.4%-0.12%-0.03%0.09%
Net Income Growth %-0.75%-4.94%0.39%0.64%6.35%
Net Income (Continuing)-72.06M-18.11M-107.66M-65.68M-23.55M126.04M
Discontinued Operations000000
Minority Interest000000
EPS (Diluted)+-2.07-0.51-0.58-0.32-0.110.53
EPS Growth %-0.75%-0.14%0.45%0.66%5.82%
EPS (Basic)-2.07-0.51-0.58-0.32-0.110.58
Diluted Shares Outstanding34.76M35.35M186.78M204.52M209.34M236.81M
Basic Shares Outstanding34.76M35.35M186.78M204.52M209.34M215.94M
Dividend Payout Ratio------

Balance Sheet

Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Total Current Assets+69.61M113.08M269.9M216.59M265.05M395.83M
Cash & Short-Term Investments60.37M100.21M247.27M179.63M220.98M300.25M
Cash Only22.65M27.34M71.78M46.77M96.66M220.58M
Short-Term Investments37.72M72.86M175.49M132.85M124.32M79.67M
Accounts Receivable859K750K3.58M3.23M6.75M6.08M
Days Sales Outstanding3.81.844.82.242.821.5
Inventory4.22M3.54M13.56M21.56M22.46M64.43M
Days Inventory Outstanding40.5632.973.4466.5952.2177.51
Other Current Assets480K5.89M890K1.78M4.2M8.9M
Total Non-Current Assets+2.46M5.61M150.68M149.75M176.13M311.71M
Property, Plant & Equipment005.11M16.14M45.73M92.96M
Fixed Asset Turnover--53.19x32.66x19.07x15.88x
Goodwill00110.88M110.88M110.88M112.73M
Intangible Assets059K25.89M21.84M18.57M43.41M
Long-Term Investments0204.53M0000
Other Non-Current Assets2.46M-198.97M8.8M889K947K1M
Total Assets+72.07M118.7M420.58M366.34M441.19M707.54M
Asset Turnover1.15x1.25x0.65x1.44x1.98x2.09x
Asset Growth %-0.65%2.54%-0.13%0.2%0.6%
Total Current Liabilities+20.62M15.23M79.22M47.94M88.47M221.37M
Accounts Payable7.23M8.07M19.64M32.36M43.07M91.18M
Days Payables Outstanding69.5474.9106.3899.94100.1109.7
Short-Term Debt1.51M00000
Deferred Revenue (Current)753K1000K1000K1000K1000K1000K
Other Current Liabilities9.1M1.57M0000
Current Ratio3.38x7.43x3.41x4.52x3.00x1.79x
Quick Ratio3.17x7.19x3.24x4.07x2.74x1.50x
Cash Conversion Cycle-25.19-40.16-28.14-31.12-45.07-30.68
Total Non-Current Liabilities+186.74M250.34M6.75M6.66M8.69M9.46M
Long-Term Debt000000
Capital Lease Obligations004.12M3.65M8.67M9.46M
Deferred Tax Liabilities000000
Other Non-Current Liabilities186.74M250.34M2.63M3.01M22K0
Total Liabilities207.36M265.57M85.97M54.6M97.16M230.82M
Total Debt+1.51M05.48M5.31M9.95M11.35M
Net Debt-21.13M-27.34M-66.3M-41.47M-86.72M-209.24M
Debt / Equity--0.02x0.02x0.03x0.02x
Debt / EBITDA-----0.14x
Net Debt / EBITDA------2.65x
Interest Coverage-201.66x-1514.40x----
Total Equity+-135.29M-146.87M334.62M311.74M344.03M476.72M
Equity Growth %--0.09%3.28%-0.07%0.1%0.39%
Book Value per Share-3.89-4.151.791.521.642.01
Total Shareholders' Equity-135.29M-146.87M334.62M311.74M344.03M476.72M
Common Stock4.5M5K20K21K21K22K
Retained Earnings-153.18M-171.29M-278.95M-344.63M-368.18M-242.14M
Treasury Stock000000
Accumulated OCI2K-11K-137K-277K-124K-324K
Minority Interest000000

Cash Flow

Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Cash from Operations+-74.87M-2.48M-34.41M-26.53M73.48M251.08M
Operating CF Margin %-0.91%-0.02%-0.13%-0.05%0.08%0.17%
Operating CF Growth %-0.97%-12.88%0.23%3.77%2.42%
Net Income-72.06M-18.11M-107.66M-65.68M-23.55M126.04M
Depreciation & Amortization260K1.06M4.08M7.47M9.52M17.09M
Stock-Based Compensation8.03M5.83M67.21M42.82M66.08M92.32M
Deferred Taxes00-3.39M-594K-13K-61.65M
Other Non-Cash Items-1.24M4.56M1.89M3.65M626K-1.34M
Working Capital Changes-9.85M4.19M3.46M-14.2M20.82M78.62M
Change in Receivables000000
Change in Inventory-522K674K-9.63M-8M-902K-41.61M
Change in Payables-6.08M826K9.85M12.72M7.32M43.71M
Cash from Investing+-39.3M-39.7M-156.27M34.7M-12.11M-19.05M
Capital Expenditures-308K-1.74M-832K-2.71M-17.22M-41.66M
CapEx % of Revenue0%0.01%0%0.01%0.02%0.03%
Acquisitions------
Investments------
Other Investing-1.48M-2.5M-4.17M-4.53M-9.27M-11.1M
Cash from Financing+95.32M47.74M235.04M-33.13M-11.47M-107.84M
Debt Issued (Net)------
Equity Issued (Net)------
Dividends Paid000000
Share Repurchases------
Other Financing-333K-2.64M-16.81M-33.13M-9.48M-24.81M
Net Change in Cash------
Free Cash Flow+-76.65M-6.71M-39.42M-33.78M46.99M198.33M
FCF Margin %-0.93%-0.05%-0.14%-0.06%0.05%0.13%
FCF Growth %-0.91%-4.87%0.14%2.39%3.22%
FCF per Share-2.21-0.19-0.21-0.170.220.84
FCF Conversion (FCF/Net Income)1.04x0.14x0.32x0.40x-3.12x1.99x
Interest Paid361K10K0000
Taxes Paid139K221K338K636K1.11M7.92M

Key Ratios

Metric201920202021202220232024
Return on Equity (ROE)---114.69%-20.32%-7.18%30.71%
Return on Invested Capital (ROIC)---183.38%-19.13%-8.37%17.69%
Gross Margin54.03%73.58%75.22%77.57%81.99%79.45%
Net Margin-87.29%-12.18%-39.6%-12.46%-2.7%8.54%
Debt / Equity--0.02x0.02x0.03x0.02x
Interest Coverage-201.66x-1514.40x----
FCF Conversion1.04x0.14x0.32x0.40x-3.12x1.99x
Revenue Growth-80.18%82.77%93.81%65.49%69.33%

Frequently Asked Questions

Valuation & Price

Hims & Hers Health, Inc. (HIMS) has a price-to-earnings (P/E) ratio of 58.9x. This suggests investors expect higher future growth.

Growth & Financials

Hims & Hers Health, Inc. (HIMS) reported $2.21B in revenue for fiscal year 2024. This represents a 2578% increase from $82.6M in 2019.

Hims & Hers Health, Inc. (HIMS) grew revenue by 69.3% over the past year. This is strong growth.

Yes, Hims & Hers Health, Inc. (HIMS) is profitable, generating $133.8M in net income for fiscal year 2024 (8.5% net margin).

Dividend & Returns

Hims & Hers Health, Inc. (HIMS) has a return on equity (ROE) of 30.7%. This is excellent, indicating efficient use of shareholder capital.

Hims & Hers Health, Inc. (HIMS) generated $131.5M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

VCP Scanner

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screens
  • Valuation
  • Compare
  • Total Return
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Twitter
  • Get Early Access
© 2026 VCP Scanner. All rights reserved.
Made with ❤️ for investors
Not financial advice. Do your own research.